MEI Pharma, Inc. - Common Stock (MEIP)
6.9986
+0.4486 (6.85%)
NASDAQ · Last Trade: Jul 22nd, 9:45 AM EDT
MEI Pharma Trades Cash For LTCstocktwits.com
Via Stocktwits · July 22, 2025
On Monday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · July 21, 2025
U.S. stock futures were positive on Monday after ending mostly lower on Friday. Futures of major benchmark indices were higher.
Via Benzinga · July 21, 2025
MEI Pharma, Inc. (NASDAQ:MEIP) stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.
Via Benzinga · July 18, 2025
MEI Pharma intends to use the funds to acquire the native cryptocurrency of the Litecoin blockchain, commonly referred to as “LTC”, which will serve as the company’s primary treasury reserve asset.
Via Stocktwits · July 18, 2025
MEI Pharma (NASDAQ:MEIP) has launched a $100 million Litecoin (CRYPTO: LTC) treasury program, backed by Titan Partners Group and
Via Benzinga · July 18, 2025
Via Benzinga · July 17, 2025
Via Benzinga · June 30, 2025

Darwin Financial's Joshua Robinson talks to Benzinga about the firm's latest commodities deal, and more M&A news from this past week.
Via Benzinga · November 22, 2024

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has the latest M&A updates.
Via Benzinga · November 17, 2024

Via Benzinga · October 25, 2024

Via Benzinga · July 22, 2024

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via InvestorPlace · July 1, 2024

Via Benzinga · May 16, 2024

MEIP stock results show that MEI Pharma beat analyst estimates for earnings per share the third quarter of 2024.
Via InvestorPlace · May 9, 2024

Via Benzinga · November 16, 2023

Via Benzinga · November 16, 2023

Companies Reporting Before The Bell • Ferguson (NYSE:FERG) is estimated to report quarterly earnings at $2.46 per share on revenue of $7.60 billion.
Via Benzinga · September 26, 2023

Infinity Pharmaceuticals Inc (NASDAQ: INFI) announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the
Via Benzinga · July 10, 2023